Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fasudil||HA-1077|AT 877||Fasudil (HA-1077) is a kinase inhibitor, especially potent against Rho-kinase, preventing downstream signaling and resulting in inhibition of cell proliferation and migration, and induction of apoptosis in cancer cells (PMID: 24908363).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL del CBLB del||bone marrow cancer||predicted - sensitive||Fasudil||Preclinical||Actionable||In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).||26177294|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|